<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome&amp;ff=20241017101040&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome&amp;ff=20241017101040&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 17 Oct 2024 14:10:44 +0000</lastbuilddate>
<pubDate>Thu, 17 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>The International Cardiomyopathy Network: a manifesto for change</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39417204/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 17:ehae692. doi: 10.1093/eurheartj/ehae692. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39417204/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39417204</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae692>10.1093/eurheartj/ehae692</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39417204</guid>
<pubDate>Thu, 17 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Perry M Elliott</dc:creator>
<dc:date>2024-10-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The International Cardiomyopathy Network: a manifesto for change</dc:title>
<dc:identifier>pmid:39417204</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae692</dc:identifier>
</item>
<item>
<title>Retraction notice to Gedatolisib Associated Acute Myocarditis in a Patient With Breast Adenocarcinoma: J Am Coll Cardiol. 2024;83(13 Suppl):3575</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39415403/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>The abstract "Gedatolisib Associated Acute Myocarditis in a Patient with Breast Adenocarcinoma" has been retracted at the request of the Editor-in-Chief because it was published before the completion of the clinical trial and full analysis of all data. There are no concerns about the findings as reported. This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/policies/article-withdrawal).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 22;84(17):1683. doi: 10.1016/j.jacc.2024.09.017.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The abstract "Gedatolisib Associated Acute Myocarditis in a Patient with Breast Adenocarcinoma" has been retracted at the request of the Editor-in-Chief because it was published before the completion of the clinical trial and full analysis of all data. There are no concerns about the findings as reported. This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/policies/article-withdrawal).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39415403/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39415403</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.017>10.1016/j.jacc.2024.09.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39415403</guid>
<pubDate>Thu, 17 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Miles Shen</dc:creator>
<dc:creator>Mohamad Khattab</dc:creator>
<dc:creator>Emmanuel Akintoye</dc:creator>
<dc:creator>Lauren Anne Baldassarre</dc:creator>
<dc:creator>Jennifer Kwan</dc:creator>
<dc:date>2024-10-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Retraction notice to Gedatolisib Associated Acute Myocarditis in a Patient With Breast Adenocarcinoma: J Am Coll Cardiol. 2024;83(13 Suppl):3575</dc:title>
<dc:identifier>pmid:39415403</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.017</dc:identifier>
</item>
<item>
<title>Heart Failure and Obesity: Unraveling Molecular Mechanisms of Excess Adipose Tissue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39415402/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>Obesity is an ongoing pandemic and is associated with the development of heart failure (HF), and especially HF with preserved ejection fraction. The definition of obesity is currently based on anthropometric measurements but neglects the location and molecular properties of excess fat. Important depots associated with HF development are subcutaneous adipose tissue and visceral adipose tissue, both located in the abdominal region, and epicardial adipose tissue (EAT) surrounding the myocardium....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 22;84(17):1666-1677. doi: 10.1016/j.jacc.2024.07.016.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Obesity is an ongoing pandemic and is associated with the development of heart failure (HF), and especially HF with preserved ejection fraction. The definition of obesity is currently based on anthropometric measurements but neglects the location and molecular properties of excess fat. Important depots associated with HF development are subcutaneous adipose tissue and visceral adipose tissue, both located in the abdominal region, and epicardial adipose tissue (EAT) surrounding the myocardium. However, mechanisms linking these different adipose tissue depots to HF development are incompletely understood. EAT in particular is of great interest because of its close proximity to the heart. In this review, we therefore focus on the characteristics of different adipose tissue depots and their response to obesity. In addition, we evaluate how different mechanisms associated with EAT expansion potentially contribute to HF and in particular HF with preserved ejection fraction development.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39415402/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39415402</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.016>10.1016/j.jacc.2024.07.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39415402</guid>
<pubDate>Thu, 17 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Just Dronkers</dc:creator>
<dc:creator>Dirk J van Veldhuisen</dc:creator>
<dc:creator>Peter van der Meer</dc:creator>
<dc:creator>Laura M G Meems</dc:creator>
<dc:date>2024-10-17</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Heart Failure and Obesity: Unraveling Molecular Mechanisms of Excess Adipose Tissue</dc:title>
<dc:identifier>pmid:39415402</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.016</dc:identifier>
</item>
<item>
<title>Multiscale drug screening for cardiac fibrosis identifies MD2 as a therapeutic target</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39413786/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>Cardiac fibrosis impairs cardiac function, but no effective clinical therapies exist. To address this unmet need, we employed a high-throughput screening for antifibrotic compounds using human induced pluripotent stem cell (iPSC)-derived cardiac fibroblasts (CFs). Counter-screening of the initial candidates using iPSC-derived cardiomyocytes and iPSC-derived endothelial cells excluded hits with cardiotoxicity. This screening process identified artesunate as the lead compound. Following...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 12:S0092-8674(24)01092-4. doi: 10.1016/j.cell.2024.09.034. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiac fibrosis impairs cardiac function, but no effective clinical therapies exist. To address this unmet need, we employed a high-throughput screening for antifibrotic compounds using human induced pluripotent stem cell (iPSC)-derived cardiac fibroblasts (CFs). Counter-screening of the initial candidates using iPSC-derived cardiomyocytes and iPSC-derived endothelial cells excluded hits with cardiotoxicity. This screening process identified artesunate as the lead compound. Following profibrotic stimuli, artesunate inhibited proliferation, migration, and contraction in human primary CFs, reduced collagen deposition, and improved contractile function in 3D-engineered heart tissues. Artesunate also attenuated cardiac fibrosis and improved cardiac function in heart failure mouse models. Mechanistically, artesunate targeted myeloid differentiation factor 2 (MD2) and inhibited MD2/Toll-like receptor 4 (TLR4) signaling pathway, alleviating fibrotic gene expression in CFs. Our study leverages multiscale drug screening that integrates a human iPSC platform, tissue engineering, animal models, in silico simulations, and multiomics to identify MD2 as a therapeutic target for cardiac fibrosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39413786/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39413786</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.034>10.1016/j.cell.2024.09.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39413786</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Hao Zhang</dc:creator>
<dc:creator>Phung N Thai</dc:creator>
<dc:creator>Rabindra V Shivnaraine</dc:creator>
<dc:creator>Lu Ren</dc:creator>
<dc:creator>Xuekun Wu</dc:creator>
<dc:creator>Dirk H Siepe</dc:creator>
<dc:creator>Yu Liu</dc:creator>
<dc:creator>Chengyi Tu</dc:creator>
<dc:creator>Hye Sook Shin</dc:creator>
<dc:creator>Arianne Caudal</dc:creator>
<dc:creator>Souhrid Mukherjee</dc:creator>
<dc:creator>Jeremy Leitz</dc:creator>
<dc:creator>Wilson Tan Lek Wen</dc:creator>
<dc:creator>Wenqiang Liu</dc:creator>
<dc:creator>Wenjuan Zhu</dc:creator>
<dc:creator>Nipavan Chiamvimonvat</dc:creator>
<dc:creator>Joseph C Wu</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Multiscale drug screening for cardiac fibrosis identifies MD2 as a therapeutic target</dc:title>
<dc:identifier>pmid:39413786</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.034</dc:identifier>
</item>
<item>
<title>Parsing Signal vs Noise-Secondary Analyses of RCTs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39412815/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 16. doi: 10.1001/jamacardio.2024.3329. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39412815/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39412815</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3329>10.1001/jamacardio.2024.3329</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39412815</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Ajay J Kirtane</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Parsing Signal vs Noise-Secondary Analyses of RCTs</dc:title>
<dc:identifier>pmid:39412815</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3329</dc:identifier>
</item>
<item>
<title>Aortic Stenosis, Heart Failure, and Aortic Valve Replacement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39412797/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: HF development in AS is multifactorial and its link to left ventricular dysfunction is a complex process. Delineating the determinants of HF admissions in AS is crucial for identifying individuals at high risk. Identifying the early signs of left ventricular decompensation by using surrogate markers may be the key, even before left ventricular function becomes impaired. Translating multimodality imaging techniques and biomarkers into routine clinical practice for...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 16. doi: 10.1001/jamacardio.2024.3486. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Heart failure (HF) and aortic stenosis (AS) frequently coexist, presenting a complex clinical challenge due to their intertwined pathophysiology and associated high morbidity and mortality. Despite numerous advancements in transcatheter and surgical aortic valve replacement (AVR), HF decompensation remains the leading cause of cardiac rehospitalization and a major predictor of mortality in patients with AS, before or after AVR. This review aims to provide a comprehensive analysis of the interplay between AS and HF, delving into myocardial changes caused by stenotic insult, the impact of AVR on these changes, and the prevalence and contributing elements of HF before and after AVR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBSERVATIONS: The prevalence of HF remains high before and after AVR, particularly among patients with left ventricular dysfunction. Increased afterload from AS causes cardiac remodeling, which is initially benign but over time these changes become maladaptive, contributing to HF and increased mortality. The progression of HF is influenced by the degree of reverse cardiac remodeling, which can be affected by comorbid conditions, the hemodynamic performance of the valve prosthesis, and vascular stiffness. Several blood and imaging biomarkers offer insights into underlying AS pathophysiology, serving as mortality predictors and predicting HF in this patient population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: HF development in AS is multifactorial and its link to left ventricular dysfunction is a complex process. Delineating the determinants of HF admissions in AS is crucial for identifying individuals at high risk. Identifying the early signs of left ventricular decompensation by using surrogate markers may be the key, even before left ventricular function becomes impaired. Translating multimodality imaging techniques and biomarkers into routine clinical practice for evaluating cardiac damage and integrating these markers with patient and procedural factors that affect HF before and after AVR can facilitate timely intervention, minimizing the likelihood of HF progression and influencing future guidelines.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39412797/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39412797</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3486>10.1001/jamacardio.2024.3486</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39412797</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Siddhartha Mengi</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>João L Cavalcante</dc:creator>
<dc:creator>Marisa Avvedimento</dc:creator>
<dc:creator>Attilio Galhardo</dc:creator>
<dc:creator>Mathieu Bernier</dc:creator>
<dc:creator>Josep Rodés-Cabau</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Aortic Stenosis, Heart Failure, and Aortic Valve Replacement</dc:title>
<dc:identifier>pmid:39412797</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3486</dc:identifier>
</item>
<item>
<title>Trends in Transcatheter Aortic Valve Replacement Outcomes: Insights From the STS/ACC TVT Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39412793/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this observational cohort study performing a national analysis of outcomes after TAVR, it was found that risk-adjusted 30-day mortality increased modestly from January 2019 to March 2022. However, no site-level, patient-related, or process-related factors were identified that could explain these findings. Although the absolute increase in risk-adjusted mortality during the study period was relatively small, these findings warrant continued surveillance.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 16. doi: 10.1001/jamacardio.2024.3453. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Although transcatheter aortic valve replacement (TAVR) outcomes in the US have improved substantially since 2011, it is unknown whether these trends have continued since 2019.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To examine changes in risk-adjusted TAVR outcomes from 2019 to 2022 and to examine any noteworthy trends over time.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This cohort study examined data from patients with severe aortic stenosis treated with TAVR at 786 US hospitals between January 1, 2019, and March 31, 2022, included in the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapies (TVT) Registry.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Patients who underwent TAVR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was 30-day mortality, and the secondary outcomes were in-hospital mortality and 30-day composite adverse events. To understand factors explaining these trends, a series of logistic regression models was constructed for each outcome, with time as the primary explanatory variable. After adjusting for changing patent characteristics and procedural factors, a series of exploratory analyses was performed to examine the extent to which these findings could be explained by several plausible hypotheses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study's analytic cohort included a total of 210 495 patients. Median (IQR) patient age was 79 (73-85) years, and 91 313 patients (43.4%) were female. Median (IQR) STS predicted risk of mortality (PROM) was 3.3% (2.0%-5.3%). There were no significant changes in unadjusted 30-day mortality from quarter 1 of 2019 (2.4%) to the end of quarter 1 of 2022 (2.2%) (P for trend = .10), with an unadjusted odds ratio (OR) for time of 0.98 per year (95% CI, 0.94-1.01). After adjusting for patient characteristics, the OR increased to 1.05 per year (95% CI, 1.02-1.08), which increased further after adjusting for procedural characteristics to 1.09 per year (95% CI, 1.05-1.13). In exploratory analyses, there were no meaningful changes in the adjusted odds of death after excluding sites that entered the STS/ACC TVT Registry in 2019 or later (OR, 1.09; 95% CI, 1.05-1.13), low-volume sites (OR, 1.09; 95% CI, 1.06-1.13), low-risk patients (OR, 1.11; 95% CI, 1.07-1.15), patients with a bicuspid aortic valve (OR, 1.09; 95% CI, 1.05-1.13), in-hospital deaths (OR, 1.08; 95% CI, 1.03-1.14), or patients who experienced a major vascular complication (OR, 1.09; 95% CI, 1.05-1.12).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this observational cohort study performing a national analysis of outcomes after TAVR, it was found that risk-adjusted 30-day mortality increased modestly from January 2019 to March 2022. However, no site-level, patient-related, or process-related factors were identified that could explain these findings. Although the absolute increase in risk-adjusted mortality during the study period was relatively small, these findings warrant continued surveillance.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39412793/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39412793</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3453>10.1001/jamacardio.2024.3453</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39412793</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Suzanne V Arnold</dc:creator>
<dc:creator>Pratik Manandhar</dc:creator>
<dc:creator>Sreekanth Vemulapalli</dc:creator>
<dc:creator>Andrzej S Kosinski</dc:creator>
<dc:creator>Wayne B Batchelor</dc:creator>
<dc:creator>Vinod H Thourani</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Trends in Transcatheter Aortic Valve Replacement Outcomes: Insights From the STS/ACC TVT Registry</dc:title>
<dc:identifier>pmid:39412793</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3453</dc:identifier>
</item>
<item>
<title>Influenza Vaccine in High-Risk Cardiovascular Diseases-Define the Target-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39412790/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 16. doi: 10.1001/jamacardio.2024.3463. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39412790/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39412790</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3463>10.1001/jamacardio.2024.3463</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39412790</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Alexander Peikert</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Orly Vardeny</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Influenza Vaccine in High-Risk Cardiovascular Diseases-Define the Target-Reply</dc:title>
<dc:identifier>pmid:39412790</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3463</dc:identifier>
</item>
<item>
<title>Coronary Revascularization Guided With Fractional Flow Reserve or Instantaneous Wave-Free Ratio: A 5-Year Follow-Up of the DEFINE FLAIR Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39412778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: At 5-year follow up, an iFR based-strategy was not statistically different than an FFR strategy to guide revascularization in terms of MACE, nonfatal myocardial infarction, and unplanned revascularization.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 16. doi: 10.1001/jamacardio.2024.3314. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The differences between the use of fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR) in the long term are unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To compare long-term outcomes of iFR- and FFR-based strategies to guide revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The DEFINE-FLAIR multicenter study randomized patients with coronary artery disease to use either iFR or FFR as a pressure index to guide revascularization. Patients from 5 continents with coronary artery disease and angiographically intermediate severity stenoses who underwent hemodynamic interrogation with pressure wires were included. These data were analyzed from March, 13, 2014, through April, 27, 2021.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME MEASURES: Five-year major adverse cardiac events (MACE) (a composite of all-cause death, nonfatal myocardial infarction, and unplanned revascularization), as well as the individual components of the combined end point.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At 5 years of follow-up, no significant differences were found between the iFR (mean age [SD], 65.5 [10.8] years; 962 male [77.5%]) and FFR (mean age [SD], 65.2 [10.6] years; 929 male [74.3%]) groups in terms of MACE (21.1% vs 18.4%, respectively; hazard ratio [HR], 1.18; 95% CI, 0.99-1.42; P = .06). While all-cause death was higher among patients randomized to iFR, it was not driven by myocardial infarction (6.3% vs 6.2% in the FFR study arm; HR, 1.01; 95% CI, 0.74-1.38; P = .94) or unplanned revascularization (11.9% vs 12.2% in the FFR group; HR, 0.98; 95% CI, 0.78-1.23; P = .87). Furthermore, patients in whom revascularization was deferred on the basis of iFR or FFR had similar MACE in both study arms (17.9% in the iFR group vs 17.5% in the FFR group; HR, 1.03; 95% CI, 0.79-1.35; P = .80) with similar rates of the components of MACE, including all-cause death. On the contrary, in patients who underwent revascularization after physiologic interrogation, the incidence of MACE was higher in the iFR group (24.6%) compared with the FFR group (19.2%) (HR, 1.36; 95% CI, 1.07-1.72; P = .01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: At 5-year follow up, an iFR based-strategy was not statistically different than an FFR strategy to guide revascularization in terms of MACE, nonfatal myocardial infarction, and unplanned revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02053038.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39412778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39412778</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3314>10.1001/jamacardio.2024.3314</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39412778</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Javier Escaned</dc:creator>
<dc:creator>Alejandro Travieso</dc:creator>
<dc:creator>Hakim-Moulay Dehbi</dc:creator>
<dc:creator>Sukhjinder S Nijjer</dc:creator>
<dc:creator>Sayan Sen</dc:creator>
<dc:creator>Ricardo Petraco</dc:creator>
<dc:creator>Manesh Patel</dc:creator>
<dc:creator>Patrick W Serruys</dc:creator>
<dc:creator>Justin Davies</dc:creator>
<dc:creator>DEFINE FLAIR Investigators</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Coronary Revascularization Guided With Fractional Flow Reserve or Instantaneous Wave-Free Ratio: A 5-Year Follow-Up of the DEFINE FLAIR Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39412778</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3314</dc:identifier>
</item>
<item>
<title>Age-Stratified Risk Categories for Cardiovascular Disease Prevention Therapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39412771/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 16. doi: 10.1001/jamacardio.2024.3544. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39412771/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39412771</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3544>10.1001/jamacardio.2024.3544</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39412771</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Cian P McCarthy</dc:creator>
<dc:creator>Kazem Rahimi</dc:creator>
<dc:creator>John W McEvoy</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Age-Stratified Risk Categories for Cardiovascular Disease Prevention Therapies</dc:title>
<dc:identifier>pmid:39412771</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3544</dc:identifier>
</item>
<item>
<title>Influenza Vaccine in High-Risk Cardiovascular Diseases-Define the Target</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39412761/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 16. doi: 10.1001/jamacardio.2024.3466. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39412761/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39412761</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3466>10.1001/jamacardio.2024.3466</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39412761</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Alberto Donzelli</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Influenza Vaccine in High-Risk Cardiovascular Diseases-Define the Target</dc:title>
<dc:identifier>pmid:39412761</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3466</dc:identifier>
</item>
<item>
<title>The heart is a muscle: on-call fitness guide for the busy cardiovascular surgeon and interventionalist</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39412259/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 16:ehae676. doi: 10.1093/eurheartj/ehae676. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39412259/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39412259</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae676>10.1093/eurheartj/ehae676</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39412259</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Samantha Colon</dc:creator>
<dc:creator>Adham Ahmed</dc:creator>
<dc:creator>Irbaz Hameed</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The heart is a muscle: on-call fitness guide for the busy cardiovascular surgeon and interventionalist</dc:title>
<dc:identifier>pmid:39412259</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae676</dc:identifier>
</item>
<item>
<title>The transformative power of women leaders in cardiology: breaking barriers and building excellence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39412225/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 16:ehae660. doi: 10.1093/eurheartj/ehae660. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39412225/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39412225</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae660>10.1093/eurheartj/ehae660</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39412225</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Gabrielle Freedman</dc:creator>
<dc:creator>Tugba Kemaloglu Oz</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The transformative power of women leaders in cardiology: breaking barriers and building excellence</dc:title>
<dc:identifier>pmid:39412225</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae660</dc:identifier>
</item>
<item>
<title>Intra-operative and post-operative management of conduits for coronary artery bypass grafting: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Surgery and the European Association for Cardio-Thoracic Surgery Coronary Task Force</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39412205/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>The structural and functional integrity of conduits used for coronary artery bypass grafting is critical for graft patency. Disruption of endothelial integrity and endothelial dysfunction are incurred during conduit harvesting subsequent to mechanical or thermal injury and during conduit storage prior to grafting, leading to acute thrombosis and early graft failure. Late graft failure, in particular that of vein grafts, is precipitated by progressive atherogenesis. Intra-operative management...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 16:ehae654. doi: 10.1093/eurheartj/ehae654. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The structural and functional integrity of conduits used for coronary artery bypass grafting is critical for graft patency. Disruption of endothelial integrity and endothelial dysfunction are incurred during conduit harvesting subsequent to mechanical or thermal injury and during conduit storage prior to grafting, leading to acute thrombosis and early graft failure. Late graft failure, in particular that of vein grafts, is precipitated by progressive atherogenesis. Intra-operative management includes appropriate selection of conduit-specific harvesting techniques and storage solutions. Arterial grafts are prone to vasospasm subsequent to surgical manipulation, and application of intra-operative vasodilatory protocols is critical. Post-operative management includes continuation of oral vasodilator therapy and selection of antithrombotic and lipid-lowering agents to attenuate atherosclerotic disease progression in conduits. In this review, the scientific evidence underlying the key aspects of intra- and post-operative management of conduits for coronary artery bypass grafting is examined. Clinical consensus statements for best clinical practice are provided, and areas requiring further research are highlighted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39412205/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39412205</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae654>10.1093/eurheartj/ehae654</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39412205</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Sigrid Sandner</dc:creator>
<dc:creator>Charalambos Antoniades</dc:creator>
<dc:creator>Etem Caliskan</dc:creator>
<dc:creator>Martin Czerny</dc:creator>
<dc:creator>Victor Dayan</dc:creator>
<dc:creator>Stephen E Fremes</dc:creator>
<dc:creator>David Glineur</dc:creator>
<dc:creator>Jennifer S Lawton</dc:creator>
<dc:creator>Matthias Thielmann</dc:creator>
<dc:creator>Mario Gaudino</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intra-operative and post-operative management of conduits for coronary artery bypass grafting: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Surgery and the European Association for Cardio-Thoracic Surgery Coronary Task Force</dc:title>
<dc:identifier>pmid:39412205</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae654</dc:identifier>
</item>
<item>
<title>Optimizing the human perinatal progenitor cell secretome for future paracrine therapy to counteract cardiac disease with AmnioSMART: an ERA4Health-funded project</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39412135/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 16:ehae550. doi: 10.1093/eurheartj/ehae550. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39412135/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39412135</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae550>10.1093/eurheartj/ehae550</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39412135</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>AmnioSMART Consortium</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Optimizing the human perinatal progenitor cell secretome for future paracrine therapy to counteract cardiac disease with AmnioSMART: an ERA4Health-funded project</dc:title>
<dc:identifier>pmid:39412135</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae550</dc:identifier>
</item>
<item>
<title>The 'ten commandments' for the 2024 European Society of Cardiology guidelines on elevated blood pressure and hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39412133/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 16:ehae646. doi: 10.1093/eurheartj/ehae646. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39412133/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39412133</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae646>10.1093/eurheartj/ehae646</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39412133</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Cian P McCarthy</dc:creator>
<dc:creator>Rhian M Touyz</dc:creator>
<dc:creator>John W McEvoy</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The 'ten commandments' for the 2024 European Society of Cardiology guidelines on elevated blood pressure and hypertension</dc:title>
<dc:identifier>pmid:39412133</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae646</dc:identifier>
</item>
<item>
<title>In memoriam: Stuart J. Connolly, MD (9 April 1949-2 June 2024)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39412132/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 16:ehae668. doi: 10.1093/eurheartj/ehae668. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39412132/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39412132</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae668>10.1093/eurheartj/ehae668</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39412132</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Stefan H Hohnloser</dc:creator>
<dc:creator>Alexander P Benz</dc:creator>
<dc:creator>Carlos A Morillo</dc:creator>
<dc:creator>Jeff S Healey</dc:creator>
<dc:creator>A John Camm</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>In memoriam: Stuart J. Connolly, MD (9 April 1949-2 June 2024)</dc:title>
<dc:identifier>pmid:39412132</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae668</dc:identifier>
</item>
<item>
<title>New editor-in-chief for European Society of Cardiology heart failure journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39412131/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 16:ehae644. doi: 10.1093/eurheartj/ehae644. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39412131/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39412131</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae644>10.1093/eurheartj/ehae644</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39412131</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jennifer Taylor</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>New editor-in-chief for European Society of Cardiology heart failure journals</dc:title>
<dc:identifier>pmid:39412131</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae644</dc:identifier>
</item>
<item>
<title>Birth of Europace: the first European specialty journal</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39412119/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 16:ehae449. doi: 10.1093/eurheartj/ehae449. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39412119/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39412119</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae449>10.1093/eurheartj/ehae449</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39412119</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Richard Sutton</dc:creator>
<dc:creator>Panos Vardas</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Birth of Europace: the first European specialty journal</dc:title>
<dc:identifier>pmid:39412119</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae449</dc:identifier>
</item>
<item>
<title>New COST Action 'EUropean network to tackle METAbolic alterations in HEART failure' (EU-METAHEART)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39412117/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 16:ehae457. doi: 10.1093/eurheartj/ehae457. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39412117/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39412117</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae457>10.1093/eurheartj/ehae457</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39412117</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Christoph Maack</dc:creator>
<dc:creator>Gemma Vilahur</dc:creator>
<dc:creator>Marisol Ruiz-Meana</dc:creator>
<dc:creator>Derek Hausenloy</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>New COST Action 'EUropean network to tackle METAbolic alterations in HEART failure' (EU-METAHEART)</dc:title>
<dc:identifier>pmid:39412117</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae457</dc:identifier>
</item>
<item>
<title>Extracellular RIPK3 Acts as a Danger-Associated Molecular Pattern to Exaggerate Cardiac Ischemia/Reperfusion Injury</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39411860/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241017101040&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: We identified the positive relationship between plasma RIPK3 concentrations and the risk of major adverse cardiovascular events in patients with acute myocardial infarction receiving PCI. As a damage-associated molecular pattern, extracellular RIPK3 plays a causal role in multiple pathological conditions during cardiac I/R injury through RAGE/CaMKII signaling. These findings expand our understanding of the physiological and pathological roles of RIPK3, and also provide a promising...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 16. doi: 10.1161/CIRCULATIONAHA.123.068595. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac ischemia/reperfusion (I/R) injury has emerged as an important therapeutic target for ischemic heart disease. Currently, there is no effective therapy for reducing cardiac I/R injury. Damage-associated molecular patterns are endogenous molecules released after cellular damage to exaggerate tissue inflammation and injury. RIPK3 (receptor-interacting protein kinase 3), a well-established intracellular mediator of cell necroptosis and inflammation, serves as a circulating biomarker of multiple diseases. However, whether extracellular RIPK3 also exerts biological functions in cardiac I/R injury remains totally unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with acute myocardial infarction receiving percutaneous coronary intervention (PCI) were recruited independently in the discovery cohort (103 patients) and validation cohort (334 patients), and major adverse cardiovascular events were recorded. Plasma samples were collected before and after PCI (6 and 24 h) for RIPK3 concentration measurement. Cultured neonatal rat ventricular myocytes, macrophages and endothelial cells, and in vivo mouse models with myocardial injury induced by I/R (or hypoxia/reoxygenation) were used to investigate the role and mechanisms of extracellular RIPK3. Another cohort including patients with acute myocardial infarction receiving PCI and healthy volunteers was recruited to further explore the mechanisms of extracellular RIPK3.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the discovery cohort, elevated plasma RIPK3 levels after PCI are associated with poorer short- and long-term outcomes in patients with acute myocardial infarction, as confirmed in the validation cohort. In both cultured cells and in vivo mouse models, recombinant RIPK3 protein exaggerated myocardial I/R (or hypoxia/reoxygenation) injury, which was alleviated by the RIPK3 antibody. Mechanistically, RIPK3 acted as a damage-associated molecular pattern and bound with RAGE (receptor of advanced glycation end-products), subsequently activating CaMKII (Ca<sup>2+</sup>/calmodulin-dependent kinase II) to elicit the detrimental effects. The positive correlation between plasma RIPK3 concentrations and CaMKII phosphorylation in human peripheral blood mononuclear cells was confirmed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We identified the positive relationship between plasma RIPK3 concentrations and the risk of major adverse cardiovascular events in patients with acute myocardial infarction receiving PCI. As a damage-associated molecular pattern, extracellular RIPK3 plays a causal role in multiple pathological conditions during cardiac I/R injury through RAGE/CaMKII signaling. These findings expand our understanding of the physiological and pathological roles of RIPK3, and also provide a promising therapeutic target for myocardial I/R injury and the associated complications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39411860/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241017101040&v=2.18.0.post9+e462414">39411860</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068595>10.1161/CIRCULATIONAHA.123.068595</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39411860</guid>
<pubDate>Wed, 16 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Wenjia Zhang</dc:creator>
<dc:creator>Junxia Zhang</dc:creator>
<dc:creator>Zeyuan Wang</dc:creator>
<dc:creator>Ting Li</dc:creator>
<dc:creator>Liu Changyun</dc:creator>
<dc:creator>Xuya Kang</dc:creator>
<dc:creator>Xiaomeng Cui</dc:creator>
<dc:creator>Jingli Yang</dc:creator>
<dc:creator>Huilin Qu</dc:creator>
<dc:creator>Jiaxin Duanmu</dc:creator>
<dc:creator>Ying Peng</dc:creator>
<dc:creator>Kai Wang</dc:creator>
<dc:creator>Li Jin</dc:creator>
<dc:creator>Peng Xie</dc:creator>
<dc:creator>Wen Zheng</dc:creator>
<dc:creator>Haibao Shang</dc:creator>
<dc:creator>Yahan Liu</dc:creator>
<dc:creator>Zhuang Tian</dc:creator>
<dc:creator>Zhenyu Liu</dc:creator>
<dc:creator>Ye Jin</dc:creator>
<dc:creator>Yingjia Li</dc:creator>
<dc:creator>Nan Li</dc:creator>
<dc:creator>Xiaozhen Zhuo</dc:creator>
<dc:creator>Yue Wu</dc:creator>
<dc:creator>Xiaolu Shi</dc:creator>
<dc:creator>Runhao Ma</dc:creator>
<dc:creator>Yueshen Sun</dc:creator>
<dc:creator>Kai Zhang</dc:creator>
<dc:creator>Xiangming Fang</dc:creator>
<dc:creator>Xiaomin Hu</dc:creator>
<dc:creator>Erdan Dong</dc:creator>
<dc:creator>Shuyang Zhang</dc:creator>
<dc:creator>Yan Zhang</dc:creator>
<dc:date>2024-10-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Extracellular RIPK3 Acts as a Danger-Associated Molecular Pattern to Exaggerate Cardiac Ischemia/Reperfusion Injury</dc:title>
<dc:identifier>pmid:39411860</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068595</dc:identifier>
</item>





























</channel>
</rss>